Malaysia Partners With Japan’s Top Oncology Hospital To Focus On Oncology Drug Development

KUALA LUMPUR, Nov 2 (Bernama) — Clinical Research Malaysia inked a Memorandum of Understanding (MoU) with the National Cancer Center Hospital to develop Malaysia’s capabilities and capacities in oncology clinical research. As one of the partners in Asia for the ATLAS (Asian clinical TriaLs network for cAncerS) project established by the National Cancer Center Japan (NCCJ), Malaysia will benefit from early phase oncology drug development, cancer genomic medicine advancement and drug access and development.

The National Cancer Center Hospital (NCCH) that will be leading this project, is the region’s leading cancer hospital located in Tokyo and was recently rated Top 20 among ‘World’s Best Specialized Hospitals 2021 in Oncology’ by Newsweek. It was designated an AMED (Japan Agency for Medical Research and Development) Global Clinical Trial Core Center in 2016 and has since scaled up its international clinical trials activities. 

http://mrem.bernama.com/viewsm.php?idm=38571

administrator

Related Articles